Abstract
The cell cycle is the series of events necessary for the division and duplication of a cell. The dysregulation of the cell cycle can promote the development of cancer. A group of proteins, cyclin-dependent kinases (CDKs), that control the cell cycle, provide new targets for treating cancer. As a result, cyclin-dependent kinase inhibitors (CDKIs) represent a novel class of chemotherapeutic agents. Of these, flavopiridol, a semisynthetic flavonoidal alkaloid, emerged as the first CDKI to enter clinical trials. Preclinical data indicate that flavopiridol could block the proliferation of neoplastic cells and induce programmed cell death as a single agent. Furthermore, recent emerging data revealed that flavopiridol can potentiate, generally in a dose- and sequence-dependent manner, the anti-tumor effects of many established chemotherapeutic agents. This review is primarily focused on the role of flavopiridol in combination with various therapeutic agents that are in or near clinical development.
Keywords: Anticancer, cancer, CDKIs, combination therapy, flavopiridol, flavonoid, Cyclin-Dependent Kinase Inhibitor, Combination Chemotherapy, Chemotherapeutic agents, Anti-tumor effects, Therapeutic agents, Mammalian enzyme systems, Dysoxylum binectariferum, Vascular endothelial growth factor (VEGF), Inhibit angiogenesis, Structure-activity relationships, Dose-limiting toxicities (DLT), Rohitukine, Oxoflavopiridols, P-TEFb, Adenine binding pocket, Pan-CDK inhibitors, Antiproliferative effect, Antiangiogenic effect, Flavopiridol's activation, Radiation-induced cytotoxicity, Docetaxel (FD), Histone Deacetylase Inhibitors (HDACIs), Cancer cell line OCA-I, Proteasome Inhibitors, Monoclonal Antibodies, Breast cancer mortality, T-cell leukemia, Gemcitabine, non-hematological malignancies, Antineoplastic agents, Gelatin microspheres (GMSs), Hyponatremia, thrombocytopenia, Neutropenia, Mitoxantrone, Humanized anti-Tac antibody, Histone deacetylase inhibitors, Hypoxia-inducible factor
Mini-Reviews in Medicinal Chemistry
Title: Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Volume: 10 Issue: 11
Author(s): L.-M. Wang and D.-M. Ren
Affiliation:
Keywords: Anticancer, cancer, CDKIs, combination therapy, flavopiridol, flavonoid, Cyclin-Dependent Kinase Inhibitor, Combination Chemotherapy, Chemotherapeutic agents, Anti-tumor effects, Therapeutic agents, Mammalian enzyme systems, Dysoxylum binectariferum, Vascular endothelial growth factor (VEGF), Inhibit angiogenesis, Structure-activity relationships, Dose-limiting toxicities (DLT), Rohitukine, Oxoflavopiridols, P-TEFb, Adenine binding pocket, Pan-CDK inhibitors, Antiproliferative effect, Antiangiogenic effect, Flavopiridol's activation, Radiation-induced cytotoxicity, Docetaxel (FD), Histone Deacetylase Inhibitors (HDACIs), Cancer cell line OCA-I, Proteasome Inhibitors, Monoclonal Antibodies, Breast cancer mortality, T-cell leukemia, Gemcitabine, non-hematological malignancies, Antineoplastic agents, Gelatin microspheres (GMSs), Hyponatremia, thrombocytopenia, Neutropenia, Mitoxantrone, Humanized anti-Tac antibody, Histone deacetylase inhibitors, Hypoxia-inducible factor
Abstract: The cell cycle is the series of events necessary for the division and duplication of a cell. The dysregulation of the cell cycle can promote the development of cancer. A group of proteins, cyclin-dependent kinases (CDKs), that control the cell cycle, provide new targets for treating cancer. As a result, cyclin-dependent kinase inhibitors (CDKIs) represent a novel class of chemotherapeutic agents. Of these, flavopiridol, a semisynthetic flavonoidal alkaloid, emerged as the first CDKI to enter clinical trials. Preclinical data indicate that flavopiridol could block the proliferation of neoplastic cells and induce programmed cell death as a single agent. Furthermore, recent emerging data revealed that flavopiridol can potentiate, generally in a dose- and sequence-dependent manner, the anti-tumor effects of many established chemotherapeutic agents. This review is primarily focused on the role of flavopiridol in combination with various therapeutic agents that are in or near clinical development.
Export Options
About this article
Cite this article as:
Wang L.-M. and Ren D.-M., Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy, Mini-Reviews in Medicinal Chemistry 2010; 10 (11) . https://dx.doi.org/10.2174/1389557511009011058
DOI https://dx.doi.org/10.2174/1389557511009011058 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Allelic Variations in CYP2D6 Gene and Susceptibility to Cervical Cancer
Drug Metabolism Letters Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Prokaryotic Arsenate Reductase Enhances Arsenate Resistance in Mammalian Cells
Recent Patents on Food, Nutrition & Agriculture Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets Recent Advances in Minimal Access Surgery for Infants and Children
Current Pediatric Reviews The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Alzheimer’s Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics
Current Alzheimer Research From TGF-β to Cancer Therapy
Current Drug Targets Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry The Prominent Role of Protein-Based Delivery Systems on the Development of Cancer Treatment
Current Pharmaceutical Design Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Hapten Recognition by T Cells: A Functional and Molecular View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design